Inovio Pharma
(INO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 218 | 832 | 10,262 | 1,775 | 7,411 |
| Gross Profit | 218 | 832 | 10,262 | 1,775 | 7,411 |
| Operating Expenses | 112,617 | 144,772 | 277,836 | 302,993 | 131,493 |
| Operating Income | -112,399 | -143,940 | -267,574 | -301,218 | -124,082 |
| Interest Expense | 178 | 1,223 | 1,254 | 1,936 | 8,703 |
| Other Income | 5,323 | 10,045 | -8,825 | -70 | -30,106 |
| Pre-tax Income | -107,254 | -135,117 | -277,653 | -303,224 | -162,890 |
| Income Tax | N/A | N/A | 2,165 | 434 | 4,585 |
| Net Income Continuous | -107,254 | -135,117 | -279,818 | -303,659 | -167,475 |
| Minority Interests | N/A | N/A | N/A | N/A | -1,064 |
| Net Income | $-107,254 | $-135,117 | $-279,818 | $-303,659 | $-166,411 |
| EPS Basic Total Ops | -3.95 | -6.09 | -14.07 | -17.45 | -12.85 |
| EPS Basic Continuous Ops | -3.95 | -6.09 | -14.07 | -17.45 | -12.96 |
| EPS Diluted Total Ops | -3.95 | -6.09 | -14.07 | -17.45 | -12.85 |
| EPS Diluted Continuous Ops | -3.95 | -6.09 | -14.07 | -17.45 | -12.96 |
| EPS Diluted Before Non-Recurring Items | -4.05 | -5.62 | -14.05 | -17.41 | -9.84 |
| EBITDA(a) | $-109,269 | $-127,939 | $-263,398 | $-294,854 | $-119,454 |